In yesterday’s Wall Street session, Puma Biotechnology Inc. (NASDAQ:PBYI) shares traded at $4.56, up 2.47% from the previous session.
As of this writing, 5 analysts cover Puma Biotechnology Inc. (NASDAQ:PBYI). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $2.00, we find $5.00. Given the previous closing price of $4.45, this indicates a potential upside of 12.36 percent. PBYI stock price is now 5.19% away from the 50-day moving average and 48.93% away from the 200-day moving average. The market capitalization of the company currently stands at $203.97M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $5.40 as their price target over the next twelve months.
With the price target maintained at $11, Citigroup recently Upgraded its rating from Neutral to Buy for Puma Biotechnology Inc. (NASDAQ: PBYI)., while ‘Goldman’ rates the stock as ‘Sell’.
In other news, Wong Alvin F, Chief Scientific Officer sold 3,460 shares of the company’s stock on Jan 03. The stock was sold for $14,456 at an average price of $4.18. Upon completion of the transaction, the Chief Scientific Officer now directly owns 54,553 shares in the company, valued at $0.25 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 03, Chief Financial Officer NOUGUES MAXIMO F sold 10,499 shares of the business’s stock. A total of $43,864 was realized by selling the stock at an average price of $4.18. This leaves the insider owning 100,427 shares of the company worth $0.46 million. Insiders disposed of 268,102 shares of company stock worth roughly $1.22 million over the past 1 year. A total of 15.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PBYI stock. A new stake in Puma Biotechnology Inc. shares was purchased by LSV ASSET MANAGEMENT during the first quarter worth $830,000. ALLY BRIDGE GROUP (NY) LLC invested $293,000 in shares of PBYI during the first quarter. In the first quarter, DIMENSIONAL FUND ADVISORS LP acquired a new stake in Puma Biotechnology Inc. valued at approximately $261,000. CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. acquired a new stake in PBYI for approximately $68,000. BALYASNY ASSET MANAGEMENT LLC purchased a new stake in PBYI valued at around $63,000 in the second quarter. In total, there are 121 active investors with 61.30% ownership of the company’s stock.
Tuesday morning saw Puma Biotechnology Inc. (NASDAQ: PBYI) opened at $4.4000. During the past 12 months, Puma Biotechnology Inc. has had a low of $1.60 and a high of $5.16. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.00, and a quick ratio of 1.90. The fifty day moving average price for PBYI is $4.3350 and a two-hundred day moving average price translates $3.0619 for the stock.
The latest earnings results from Puma Biotechnology Inc. (NASDAQ: PBYI) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at $0.21, beating analysts’ expectations of $0 by 0.21. This compares to -$1.09 EPS in the same period last year. The net profit margin was 4.50% and return on equity was 84.40% for PBYI. The company reported revenue of $57.1 million for the quarter, compared to $46.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.48 percent. For the current quarter, analysts expect PBYI to generate $50.13M in revenue.
Puma Biotechnology Inc.(PBYI) Company Profile
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company’s drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
